Cargando…

Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva)

Temsirolimus is a prodrug form of sirolimus (rapamycin). With its analogs (everolimus, ridaforolimus, and rapamycin), it forms a group of anticancer agents that block the activity of one of the two mammalian targets of rapamycin (mTOR) complexes, mTORC1. We investigated the emetic potential of varyi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belkacemi, Louiza, Sun, Yina, Darmani, Nissar A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014009/ https://www.ncbi.nlm.nih.gov/pubmed/35444553 http://dx.doi.org/10.3389/fphar.2022.848673

Ejemplares similares

The Contribution of Phospholipase C in Vomiting in the Least Shrew (Cryptotis Parva) Model of Emesis
por: Zhong, Weixia, et al.
Publicado: (2021)

The HCN Channel Blocker ZD7288 Induces Emesis in the Least Shrew (Cryptotis parva)
por: Zhong, W., et al.
Publicado: (2021)

Physical and Cognitive Performance of the Least Shrew (Cryptotis parva) on a Calcium-Restricted Diet
por: Czajka, Jessica L., et al.
Publicado: (2012)

RNA sequencing least shrew (Cryptotis parva) brainstem and gut transcripts following administration of a selective substance P neurokinin NK(1) receptor agonist and antagonist expands genomics resources for emesis research
por: Irizarry, Kristopher J. L., et al.
Publicado: (2023)

Serotonin 5-HT(3) Receptor-Mediated Vomiting Occurs via the Activation of Ca(2+)/CaMKII-Dependent ERK1/2 Signaling in the Least Shrew (Cryptotis parva)
por: Zhong, Weixia, et al.
Publicado: (2014)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

Evaluating the activity of temsirolimus in neuroendocrine cancer
por: O'Donnell, P H, et al.
Publicado: (2007)

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer
por: Duran, I, et al.
Publicado: (2007)

Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
por: Boyle, H., et al.
Publicado: (2011)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Profile of temsirolimus in the treatment of advanced renal cell carcinoma
por: Staehler, Michael, et al.
Publicado: (2010)

Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
por: Hadoux, Julien, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
por: Venugopal, Balaji, et al.
Publicado: (2013)

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model
por: Chang, Hsuen-Wen, et al.
Publicado: (2018)

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center
por: Afshar, Mehran, et al.
Publicado: (2014)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype
por: Gabriel, Diana, et al.
Publicado: (2016)

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
por: Kaley, Thomas J., et al.
Publicado: (2020)

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
por: Infante, Jeffrey R., et al.
Publicado: (2017)

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma
por: Wang, Li, et al.
Publicado: (2010)

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
por: Verschraegen, Claire F., et al.
Publicado: (2013)

Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus
por: Briggs, Joseph W., et al.
Publicado: (2017)

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2019)

Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting
por: Darmani, Nissar A.
Publicado: (2010)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
por: Duran, I, et al.
Publicado: (2006)

Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer
por: Zardavas, Dimitrios, et al.
Publicado: (2011)

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab
por: Wagenseller, Aubrey G, et al.
Publicado: (2013)

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
por: Pulido, Marina, et al.
Publicado: (2018)

A case of delayed exacerbation of interstitial lung disease after discontinuation of temsirolimus
por: Matsuki, Rei, et al.
Publicado: (2017)

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
por: Yang, S, et al.
Publicado: (2010)

Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report
por: JURADO, JOSÉ MIGUEL, et al.
Publicado: (2013)

Metastatic clear cell renal carcinoma – an unusual response to Temsirolimus in second line therapy
por: Stanculeanu, DL, et al.
Publicado: (2016)

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells
por: Juengel, Eva, et al.
Publicado: (2017)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
por: Le Tourneau, C, et al.
Publicado: (2008)

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
por: Wang-Gillam, Andrea, et al.
Publicado: (2014)

Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
por: Satoh, Tendo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_09vgbssmsothbmokobg3hijkur